1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow ER Positive Breast Cancer: new trials by email Literature Review of ER Positive Breast Cancer trials Research Report on ER Positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Palazestrant, Letrozole-matching placebo, Ribociclib - Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Recruiting | Olema Pharmaceuticals, Inc. | 1000 | 2025-11-03 | 2026-09-23 |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Palazestrant, Fulvestrant, Anastrozole - Breast Cancer, Advanced Breast Cancer | Phase 3 | Active not recruiting | Olema Pharmaceuticals, Inc. | 510 | 2023-11-16 | 2026-08-13 |
Breast Neoplasms (2)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Letrozole (2) · Anastrozole (1) · Fulvestrant (1) · exemestane (1) · ribociclib (1)
Olema Pharmaceuticals, Inc. (2)
Australia (2) · Austria (2) · Belgium (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Hong Kong (2) · Hungary (2) · Italy (2) · Malaysia (2) · Netherlands (2) · Poland (2) · Portugal (2) · Romania (2)